You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Claims for Patent: 7,071,158

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,071,158

Title:	Antioxidant enhancement of therapy for hyperproliferative conditions
Abstract:	A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.
Inventor(s):	Chinery; Rebecca (Nashville, TN), Beauchamp; R. Daniel (Nashville, TN), Coffey; Robert J. (Woodside, CA), Medford; Russell M. (Atlanta, GA), Wadzinski; Brian E. (Nashville, TN)
Assignee:	Atherogenics, Inc. (Norcross, GA)
Application Number:	09/779,086
Patent Claims:	1. A method to enhance the cytotoxicity of an antineoplastic drug for the treatment of a disorder of abnormal cell proliferation, the method comprising administering an effective amount of the antineoplastic drug to a host in need of such treatment in combination with an effective cytotoxicity-increasing amount of an antioxidant, wherein the antioxidant is a mono-ester or di-ester of probucol. 2. The method according to claim 1 wherein the mono-ester or di-ester of probucol is an ester of succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid or maleic acid. 3. The method of claim 1, wherein the antineoplastic agent is selected from the group consisting of Aceglatone; Aclarubicin; Altretamine; Aminoglutethimide; 5-Aminogleavulinic Acid; Amsacrine; Anastrozole; Ancitabine Hydrochloride; 17-1A Antibody; Antilymphocyte Immunoglobulins; Antineoplaston A10; Asparaginase; Pegaspargase; Azacitidine; Azathioprine; Batimastat; Benzoporphyrin Derivative; Bicalutamide; Bisantrene Hydrochloride; Bleomycin Sulphate; Brequinar Sodium; Broxuridine; Busulphan; Campath-IH; Caracemide; Carbetimer; Carboplatin; Carboquone; Carmofur; Carmustine; Chlorambucil; Chlorozotocin; Chromomycin; Cisplatin; Cladribine; Corynebacterium parvum; Cyclophosphamide; Cyclosporin; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Diaziquone; Dichlorodiethylsulphide; Didemnin B.; Docetaxel; Doxifluridine; Doxorubicin Hychloride; Droloxifene; Echinomycin; Edatrexate; Elliptinium; Elmustine; Enloplatin; Enocitabine; Epirubicin Hydrochloride; Estramustine Sodium Phosphate; Etanidazole; Ethoglucid; Etoposide; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flutamide; Formestane; Fotemustine; Gallium Nitrate; Gencitabine; Gusperimus; Homoharringtonine; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Improsulfan Tosylate; Inolimomab; Interleukin-2; Irinotecan; JM-216; Letrozole; Lithium Gamolenate; Lobaplatin; Lomustine; Lonidamine; Mafosfamide; Meiphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Miboplatin; Miltefosine; Misonidazole; Mitobronitol; Mitoguazone Dihydrochioride; Mitolactol; Mitomycin; Mitotane; Mitozanetrone Hydrochloride; Mizoribine; Mopidamol; Muitlaichilpeptide; Muromonab-CD3; Mustine Hydrochloride; Mycophenolic Acid; Mycophenolate Mofetil; Nedaplatin; Nilutamide; Nimustine Hydrochloride; Oxaliplatin; Paclitaxel; PCNU; Penostatin; Peplomycin Sulphate; Pipobroman; Pirarubicin; Piritrexim Isethionate; Piroxantrone Hydrochloride; Plicamycin; porfimer Sodium; Prednimustine; Procarbazine Hydrochloride; Raltitrexed; Ranimustine; Razoxane; Rogletimide; Roquinimex; Sebriplatin; Semustine; Sirolimus; Sizofiran; Sobuzoxane; Sodium Bromebrate; Sparfosic Acid; Sparfosate Sodium; Sreptozocin; Sulofenur; Tacrolimus; Tamoxifen; Tegafur; Teloxantrone Hydrochloride; Temozolomide; Teniposide; Testolactone; Tetrasodium Mesotetraphenylporphine-sulphonate; Thioguanine; Thioinosine; Thiotepa; Topotecan; Toremifene; Treosulfan; Trimetrexate; Trofosfamide; Tumor Necrosis Factor; Ubenimex; Uramustine; Vinblastine Sulphate; Vincristine Sulphate; Vindesine Sulphate; Vinorelbine Tartrate; Vorozole; Zinostatin; Zolimomab Aritox; and Zorubicin Hydrochloride. 4. The method of claim 1, wherein the abnormal cell proliferation is a hyperproliferative or preneoplastic lesion. 5. The method according to claim 1, wherein the antineoplastic drug is carboplatin. 6. The method according to claim 1, wherein the antineoplastic drug is cisplatin. 7. The method according to claim 1, wherein the antineoplastic drug is doxorubicin. 8. The method according to claim 1, wherein the antineoplastic drug is daunorubicin. 9. The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-succinic acid ester. 10. The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-glutaric acid ester. 11. The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-adipic acid ester. 12. The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-suberic acid ester. 13. The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-azelaic acid ester. 14. The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-maleic acid ester.

Details for Patent 7,071,158

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	⤷ Start Trial	2021-02-07
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	February 01, 1994	⤷ Start Trial	2021-02-07
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	September 14, 1992	⤷ Start Trial	2021-02-07
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Start Trial	2021-02-07
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Start Trial	2021-02-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.